Clinical Trials Logo

Vaginal Atrophy clinical trials

View clinical trials related to Vaginal Atrophy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04159493 Withdrawn - Vaginal Atrophy Clinical Trials

A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy

DOVE
Start date: June 5, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, dose-de-escalation study whose purpose is to establish the lowest efficacious dose. The first 40 subjects will be randomized 1:1:1:1 to either 500 mcg, 50 mcg, 10 mcg, or placebo. After four weeks of dosing with 500 mcg, vaginal pH, vaginal maturation index, and subject's most bothersome moderate to severe symptom will be assessed; the changes observed will be used as the benchmark for efficacy throughout the remainder of the study and select the next dose-level to be investigated. Subjects will be enrolled in small cohorts at various doses until the lowest effective dose is identified. Then, 1 to 2 doses and a placebo group will be expanded to enroll 70 subjects per treatment group.